Day-of-surgery rejection of donors in living donor liver transplantation

Abstract

The laparoscopic assessment of donors in LDLT is a safe and acceptable procedure that avoids unnecessary large abdominal incisions and increases the chance of achieving donor safety.

Outcome after living donor liver transplantation: A comprehensive retrospective analysis of the risk factors for morbidity, mortality and graft failure in a tertiary care center

“…Their use are justified when they are not associated with other risk factors. Liver biopsy is recommended in countries where there is lack of expertise in the evaluation and diagnosis of hepatic steatosis by radiological means [52]. It also serves to detect other pathological conditions in the donor such as hepatitis, fibrosis or cirrhosis, which may be prevalent in these countries.…”

Utility of Bone Scan in Hcc Patients in Pre-Liver Transplant Work-Up

“…Once a diagnosis of HCC has been confirmed, disease staging is essential for treatment selection [1]. Curative treatments, such as resection or liver transplantation (LT), are offered to patients with early stage tumors according to the Barcelona Clinic Liver Cancer Group (BCLC) classification [1], that is, patients with a single lesion <5 cm or up to three lesions ≤3 cm without macrovascular invasion.…”

“…Curative treatments, such as resection or liver transplantation (LT), are offered to patients with early stage tumors according to the Barcelona Clinic Liver Cancer Group (BCLC) classification [1], that is, patients with a single lesion <5 cm or up to three lesions ≤3 cm without macrovascular invasion. These criteria, known as the Milan criteria [12], identify a group of patients with HCC who may experience good disease-free survival after LT and outcomes comparable to those of patients receiving LT for other indications.…”

“…Hepatocellular carcinoma (HCC) is the most common primary liver tumor accounts for over 80 % [1,2] and the burden of this devastating disease is expected to increase. HCC is the second leading cause of cancer-related death worldwide [3].…”

Mortality in Patients with Potential Living Donor Liver

“…Other causes include significant fibrotic changes in 15(16%), significant portal lymphocytic infiltrate in 13(14%), active hepatitis 3(3%), shistosomiasis in 3(3%) and other rare disorders in another 4(4%). Even after liver biopsy, few cases were canceled the same day of surgery mainly due to gross abnormality in the liver [9].…”